About the Company

Ignyta, Inc. (NasdaqCM: RXDX) is a precision medicine company developing oncology assets via an integrated drug and companion diagnostic approach known as Rx/Dx. Ignyta’s lead clinical candidate, entrectinib, is an oral, potential first-in-class tyrosine kinase inhibitor of TrkA, TrkB, TrkC, ROS1, and ALK. Entrectinib is currently being tested in two Phase I/II clinical studies. The Company intends to target several unique, molecularly defined patient populations in Phase II dose expansion cohorts to identify the most appropriate indications for later trials. Ignyta recently expanded its pipeline by in-licensing 4 programs from Teva, substantially increasing the Company’s market opportunity, and allowing the use of an umbrella trial design going forward for more efficient drug testing.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research